Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CBFB | Q13951 | 3/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15671156 | 0.96 | CYP1A2 (0.42) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL13524542 | 0.82 | CCNB2 (0.43) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL5489687 | 0.78 | CYP1A2 (0.41) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL28216733 | 0.76 | GPR84 (0.41) | CTSVCTSLGPR84PARP1KMT2A | |
| SCHEMBL7137809 | 0.74 | CYP1A2 (0.43) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL12824823 | 0.74 | CYP1A2 (0.34) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL15671175 | 0.73 | CYP1A2 (0.42) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL28448529 | 0.73 | LIPG (0.49) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL21565085 | 0.73 | LIPG (0.49) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL2661126 | 0.72 | CYP1A2 (0.41) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005024058-A2 | COMPOUNDS FOR THE TREATMENT OF DISEASES INVOLVING COGNITIVE IMPAIRMENT, SUCH AS ALZHEIMER’S DISEASE, AND METHODS FOR IDENTIFYING SUCH COMPOUNDS | GALAPAGOS N.V. (BE) | 2005-03-17 | — | — | WO | claimed |
| EP-2327709-B1 | Modulation of glucagon receptor expression | IONIS PHARMACEUTICALS INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-8642753-B2 | Modulation of glucagon receptor expression | ISIS PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120295958-A1 | MODULATION OF GLUCAGON RECEPTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2327709-A2 | Modulation of glucagon receptor expression | ISIS Pharmaceuticals, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7919476-B2 | Modulation of glucagon receptor expression | ISIS PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-2272857-A1 | Modulation of glucagon receptor expression | ISIS Pharmaceuticals, Inc. (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100234447-A1 | MODULATION OF GLUCAGON RECEPTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7750142-B2 | Modulation of glucagon receptor expression | ISIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7446106-B2 | Pyridylfurans and pyrroles as Raf kinase inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20070238688-A1 | MODULATION OF GLUCAGON RECEPTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070238687-A1 | MODULATION OF GLUCAGON RECEPTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070238689-A1 | MODULATION OF GLUCAGON RECEPTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070238690-A1 | MODULATION OF GLUCAGON RECEPTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. | 2007-10-11 | — | — | US | disclosed |
| WO-2005024058-A2 | COMPOUNDS FOR THE TREATMENT OF DISEASES INVOLVING COGNITIVE IMPAIRMENT, SUCH AS ALZHEIMER’S DISEASE, AND METHODS FOR IDENTIFYING SUCH COMPOUNDS | GALAPAGOS N.V. (BE) | 2005-03-17 | — | — | WO | disclosed |
| US-20050014713-A1 | Modulation of glucagon receptor expression | ISIS PHARMACEUTICALS, INC. | 2005-01-20 | — | — | US | disclosed |
| US-20040266714-A1 | Modulation of glucagon receptor expression | ISIS PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040198730-A1 | Pyridylfurans and pyrroles as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1432699-A1 | PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003022832-A1 | PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198730-A1 | Pyridylfurans and pyrroles as raf kinase inhibitors | BRAF, ARAF, RAF1 | CYP1A2 2926/4885CYP2D6 3303/4885CYP19A1 3363/4885 |
| US-20100234447-A1 | MODULATION OF GLUCAGON RECEPTOR EXPRESSION | GCGR, GIPR, GLP1R | CYP1A2 4875/4885CYP2D6 4837/4885CYP19A1 3325/4885 |
| US-20120295958-A1 | MODULATION OF GLUCAGON RECEPTOR EXPRESSION | GCGR, GIPR, GLP1R | CYP1A2 4875/4885CYP2D6 4837/4885CYP19A1 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.